Cancer News
OncoLink Cancer News - HealthDay

Extended Interferon Not Found Beneficial in Melanoma

-- Rick Ansorge

Wednesday, January 6, 2010

WEDNESDAY, Jan. 6 (HealthDay News) -- In patients with intermediate and high-risk primary melanoma, continuation of low-dose interferon therapy beyond 18 months is not beneficial, according to a study published online Jan. 4 in the Journal of Clinical Oncology.

Axel Hauschild, M.D., of the University of Kiel in Germany, and colleagues studied 850 patients who were randomly assigned to receive low-dose interferon therapy three times a week for either 18 or 60 months.

The researchers found that there were no significant group differences in relapse-free survival (75.6 versus 72.6 percent), distant-metastasis-free survival (81.9 versus 79.7 percent), and overall survival (85.9 versus 84.9 percent).

"In conclusion, the results of our trial indicate that low-dose interferon alpha for patients who are lymph node negative should not be extended beyond the routine duration of 18 months," the authors write.

The study was supported by Roche Pharma AG, Grenzach-Wyhlen, and Roche Austria GmbH; several authors reported financial relationships with these companies.

Full Text (subscription or payment may be required)

Specialties Cardiology
Diabetes & Endocrinology
Internal Medicine
Family Practice

Copyright © 2010 ScoutNews, LLC. All rights reserved.

I Wish You Knew

How an oncology social worker can improve your cancer experience

View More

Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.

OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More